Effect of Tolpa Peat Preparation on Selected Immune Parameters in Healthy Volunteers. Preliminary Data
Abstract:
Investigations of selected immune parameters were carried out on healthy humans receiving TPP in doses of 50, 100, 300 and 600 mg daily for 14 days. The following factors were analyzed: percentage and composition of T lymphocyte subsets, the ability to generate interleukin-1 (Il-1) and interleukin-2 (Il-2), and spontaneous and PHA- stimulated expression of receptors for Il-2 (TAC) and transferrin receptor (Tr) on lymphocytes. The following factors were evaluated: lymphocyte proliferation induced with mitogens and alloantigens and generation of Tumor Necrosis Factor a (TNFa) by monocytes and superoxide radicals by granulocytes. A 50 mg dose of TPP did not change either the T-cell percentage among mononuclear cells or the composition of T-cell subsets. A higher dosage of 100 mg of TPP caused a significant increase in the percentage of T-cells on the 14th day but did not influence their subset composition. On the 14th and 28th days of observation, a statistically significant decrease of Il-2 generation was observed but there was no change of TAC receptor expression on lymphocytes or the ability to generate Il-1 by monocytes. In the doses of 50 and 100 mg, TPP caused a slight immunomodulating potential in healthy humans, however the immunological parameters that were evaluated remained within the norm. Considerable differences were found in other immune parameters that were examined during the administration of higher TPP doses in human groups consisting of four volunteers, but individual differences in small experimental groups and the lack of a placebo group do not justify definite conclusions and the results can only be considered to be preliminary.
Authors:
Baj, Z. et al.
Abbreviated Journal Title: Acta Pol Pharm
Date of Publication: 1993
Journal Volume: 50
Page Numbers: 481 through 489
Country of Publication: Poland
Language of Article: English
Issue/Part/Supplement: 6
ISSN: 0001-6837
MESH Headings:
Peat Preparation
Tumor Necrosis Factor
Immune System
Published with permission from Acta Poloniae Pharmaceutica - Drug Research